{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ethyl-eicosapentanoic+acid+%28ethyl-EPA%29&page=2",
    "query": {
      "intervention": "Ethyl-eicosapentanoic acid (ethyl-EPA)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 39,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ethyl-eicosapentanoic+acid+%28ethyl-EPA%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ethyl-eicosapentanoic+acid+%28ethyl-EPA%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T01:03:47.393Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01431690",
      "title": "Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "warfarin",
          "type": "DRUG"
        },
        {
          "name": "omefas",
          "type": "DRUG"
        },
        {
          "name": "omega-3-acid ethyl esters",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2011-08",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2015-04-24",
      "last_synced_at": "2026-10-07T01:03:47.393Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431690"
    },
    {
      "nct_id": "NCT00915902",
      "title": "Fish Oil Study for High Triglyceride Levels in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Omega-3-acid ethyl esters",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Babu Balagopal",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 42,
      "start_date": "2009-07",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-10-07T01:03:47.393Z",
      "location_count": 3,
      "location_summary": "Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00915902"
    },
    {
      "nct_id": "NCT00001146",
      "title": "Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Involutional Depression",
        "Mood Disorder"
      ],
      "interventions": [
        {
          "name": "Ethyl Eicosapentaenoic Acid",
          "type": "DRUG"
        },
        {
          "name": "OmegaBrite",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 240,
      "start_date": "1999-10",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-07T01:03:47.393Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001146"
    },
    {
      "nct_id": "NCT04177680",
      "title": "Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Omega 3 pentaenoic acid",
          "type": "DRUG"
        },
        {
          "name": "icosapent ethyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matinas BioPharma Nanotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-06-03",
      "completion_date": "2021-01-18",
      "has_results": true,
      "last_update_posted_date": "2022-03-04",
      "last_synced_at": "2026-10-07T01:03:47.393Z",
      "location_count": 8,
      "location_summary": "Jacksonville, Florida • Jupiter, Florida • Port Saint Lucie, Florida + 5 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Addison",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04177680"
    },
    {
      "nct_id": "NCT01208961",
      "title": "Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Epanova (4 g) and Lovaza (4 g)",
          "type": "DRUG"
        },
        {
          "name": "Lovaza (4 g) and Epanova (4 g)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2010-09",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2015-07-15",
      "last_synced_at": "2026-10-07T01:03:47.393Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01208961"
    },
    {
      "nct_id": "NCT00096798",
      "title": "Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Ethyl-eicosapentanoic acid (ethyl-EPA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Center for Complementary and Integrative Health (NCCIH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2001-09",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2008-01-17",
      "last_synced_at": "2026-10-07T01:03:47.393Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096798"
    },
    {
      "nct_id": "NCT05198843",
      "title": "Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Triple-Negative Breast Inflammatory Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Icosapent Ethyl",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2022-11-08",
      "completion_date": "2023-12-20",
      "has_results": true,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-10-07T01:03:47.393Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05198843"
    },
    {
      "nct_id": "NCT03443076",
      "title": "Bioavailability of EPA + DHA in a SMEDS Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bioavailability"
      ],
      "interventions": [
        {
          "name": "EPA + DHA in SMEDS Formulation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Lovaza (active comparator; already FDA approved)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Midwest Center for Metabolic and Cardiovascular Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-02-16",
      "completion_date": "2018-04-15",
      "has_results": false,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-10-07T01:03:47.393Z",
      "location_count": 2,
      "location_summary": "Boca Raton, Florida • Chicago, Illinois",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03443076"
    },
    {
      "nct_id": "NCT00069784",
      "title": "The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Non-Insulin-Dependent"
      ],
      "interventions": [
        {
          "name": "insulin glargine (HOE901)",
          "type": "DRUG"
        },
        {
          "name": "omega-3 polyunsaturated fatty acids (PUFA)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "reusable pen device for insulin injection",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12537,
      "start_date": "2003-08",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-10-07T01:03:47.393Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069784"
    },
    {
      "nct_id": "NCT04505098",
      "title": "A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Covid19",
        "Atherosclerosis",
        "Cardiovascular Diseases",
        "Upper Respiratory Tract Infections"
      ],
      "interventions": [
        {
          "name": "Icosapent ethyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 39600,
      "start_date": "2020-08-07",
      "completion_date": "2022-12-15",
      "has_results": false,
      "last_update_posted_date": "2023-07-18",
      "last_synced_at": "2026-10-07T01:03:47.393Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505098"
    }
  ]
}